METrix: MET Overexpression in Patients with Non-Small Cell Lung Cancer
Research type
Research Study
Full title
International Real-World Study of MET Overexpression in Patients with Non-Small Cell Lung Cancer (METrix study)
IRAS ID
329672
Contact name
Rachel Horsfall
Contact email
Sponsor organisation
AbbVie Ltd
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 10 months, 4 days
Research summary
This is a non-interventional (patients will not receive a medication as part of the study) retrospective (information is collected using past medical records and samples), multi-center (approximately 2-4 hospitals), United Kingdom (UK)-based study. Patient tissue samples collected between 01 January 2019 and present day will be analysed by local labs for MET protein expression status by immunohistochemistry (IHC) (a lab technique that uses antibodies to detect the location of proteins and other antigens in tissue sections). Tissue samples will also be sent to a central lab in the United States (US) for concordance (checking consistency) testing. The study will aim to recruit up to 60 patients (aged 18 years or older), with newly diagnosed (confirmation of illness) or relapsed / refractory advanced or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC). Data capture will involve a retrospective chart review, where research staff will enter data (local labs) and the study sponsor (AbbVie) (data from central lab) analysed from the tissue samples into an electronic case report form (eCRF). Analyses will include MET over-expression (OE) and overlap between MET OE. In addition, sites will enter data into the eCRF if readily available including other driver mutations (changes) (e.g. EGFR), other relevant biomarkers and additional molecular alterations (changes) (e.g. PD-L1 expression). Sites will also provide information on diagnosis, tumor location, treatment history, imaging, results from other molecular testing performed before the current study, demographics, and overall survival will be provided by the local pathologist or clinician. This will allow the assessment of the prevalence (how common) of MET OE and OE high according to the line of therapy (describes order of different treatments received) and the type of treatment received by the patient. Information collected will not be health-actionable. The study is sponsored and funded by AbbVie Ltd.
REC name
London - Riverside Research Ethics Committee
REC reference
23/LO/0847
Date of REC Opinion
19 Oct 2023
REC opinion
Further Information Favourable Opinion